Recently, it has been revealed that SHARP1 has oncogenic properties in MLL-AF6 Acute Myeloid Leukemia (AML), which has the worst prognosis among all subtypes of MLL-rearranged AMLs [8], indicating that SHARP1 can act either as an oncoprotein or a tumor suppressor depending on the cancer type. This evidence concerns the gene KMT2A and cancer.